Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Breaking News, Finance

18 Aug 2022

Breaking News: MindMed Stock Jumps Over 60%

Investors woke up this morning to a serious shroom stock buzz....

By Jason Najum

Breaking News, Industry

12 Aug 2022

Breaking News: MindMed Halts 18-MC (MM-110) Opioid Withdrawal Program

Yesterday MindMed released its financial results and held its earnings call, announcing the shelving of its 18-MC (MM-110) program for opioid withdrawal....

By Jason Najum

Culture

11 Aug 2022

Update: Psychedelics in the Media

Let's take a look at recent psychedelic medicine headlines and see what the media has been saying as of late....

By Jason Najum

Industry, Science

10 Aug 2022

Democratizing Health Research: An Interview with Quantified Citizen

Quantified Citizen is an app and digital platform that allows researchers to access large numbers of participants for a variety of studies, while simultaneously giving people the opportunity to self-examine...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

27 Jul 2022

Roth Capital Doubles Down on Small Pharma

Roth analyst Elemer Piros has doubled down on Small Pharma, citing the IP value of this new patent....

By Jason Najum

Industry

22 Jul 2022

A Deeper Look at MindMed’s Corporate Update

MindMed has released its Corporate Overview....

By Jason Najum

Industry

19 Jul 2022

COMPASS Pathways Appoints Big Pharma CEO

Compass Pathways' George Goldsmith is replaced by Kabir Nath, former Senior Director at pharma giant Otsuka Pharmaceuticals....

By Jason Najum

Culture

18 Jul 2022

A Look at Michael Pollan’s Psychedelics Documentary on Netflix

Michael Pollan's psychedelics documentary is now playing on Netflix, a four-part documentary on the history, renaissance, and potential of psychedelics....

By Jason Najum

Finance

15 Jul 2022

Market Update: An Interview With Roth Capital Analyst

Microdose's editor Jason Najum sits down with Roth Capital analyst Elemer Piros for a discussion on the state of the psychedelic medicine market....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.